Abstract
Reactivation of mutant p53 is likely to provide important benefits for treatment of chemotherapy- and radiotherapy-resistant tumors. We demonstrate here that the maleimide-derived molecule MIRA-1 can reactivate DNA binding and preserve the active conformation of mutant p53 protein in vitro and restore transcriptional transactivation to mutant p53 in living cells. MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. The structural analog MIRA-3 showed antitumor activity in vivo against human mutant p53-carrying tumor xenografts in SCID mice. The MIRA scaffold is a novel lead for the development of anticancer drugs specifically targeting mutant p53. © 2005 by The American Society for Biochemistry and Molecular Biology, Inc.
Cite
CITATION STYLE
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., … Wiman, K. G. (2005). Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. Journal of Biological Chemistry, 280(34), 30384–30391. https://doi.org/10.1074/jbc.M501664200
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.